Loading...
Loading...
RVPH| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 7,450.2K |
| Operating I/L | -7,450.2K |
| Other Income/Expense | 88.8K |
| Interest Income | 0.0K |
| Pretax | -7,361.4K |
| Income Tax Expense | 3.6K |
| Net Income/Loss | -7,365.0K |
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in developing next-generation therapeutics for central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Their lead product candidate, RP5063, is in Phase III clinical trials for schizophrenia treatment and has completed Phase I trials for various other conditions. Additionally, the company is developing RP1208 for depression and obesity treatment. By advancing these innovative therapies through clinical trials and potential commercialization, Reviva Pharmaceuticals aims to generate revenue from the sale of these therapeutics to address unmet medical needs in multiple disease areas.
